Oncology groups and doctors fight for lower-priced cancer treatments
October 9, 2015Medical Communications, Research and Development, Sales and Marketing
Oncology groups such as the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) are working …
Sanofi looks to increase productivity in France by 25%
October 9, 2015Manufacturing and Production, Medical Communications Sanofi
Sanofi is looking for a deal with unions in order to boost productivity by 20-25% at French plants over three …
Merck announces positive Elbasvir/Grazoprevir trial results
October 9, 2015Research and Development
Merck has announced the publication of results from C-SURFER, the first Phase III clinical trial to investigate an all-oral, ribavirin-free …
AstraZeneca’s Moventig now available through NHS
October 9, 2015Medical Communications, Research and Development, Sales and Marketing AstraZeneca, moventig
AstraZeneca has announced that Moventig (naloxegol) has been made available for adult patients with opioid-induced constipation (OIC) in England and …
Taking on IFP, COPD and severe asthma: ERS 2015 roundup
October 9, 2015Medical Communications, Research and Development
Leading pharmaceutical companies, physicians, healthcare professionals, scientists, respiratory experts, and of course the media, including Pharmafocus, gathered in Amsterdam at the …
Ovid Therapeutics appoints Dr Jerome B. Zeldis to Its Scientific Advisory Board
October 9, 2015Medical Communications
Ovid Therapeutics, a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, has …
Positive late-stage results for Genentech’s ocrelizumab in different forms of MS
October 8, 2015Research and Development ECTRIMS, Genentech, MS, Roche, multiple sclerosis, ocrelizumab
Roche’s biotech arm Genentech has presented ‘transformative’ data at an international multiple sclerosis conference on its investigational drug ocrelizumab. Ocrelizumab …
Innovative pipeline can transform obesity treatment, says GBI Research
October 8, 2015Research and Development obesity
While the current obesity treatment market has a high level of unmet need, the therapeutic landscape could be transformed by …
Simple blood test can accurately predict imminent heart attacks
October 8, 2015Research and Development NHS, heart attack
A simple blood test which predicts whether a patient suffering chest pains will have a heart attack has the potential to save …
Novartis looks to new measure of Gilenya outcomes
October 8, 2015Research and Development fingolimod, gilenya, multiple sclerosis, relapsing multiple sclerosis
Novartis says a new analysis from two Phase III trials reinforces the long-term efficacy profile of its MS treatment Gilenya. …
UCB plots new Vimpat submissions after positive monotherapy results
October 8, 2015Research and Development EMA, European Medicines Agency, UCB, carbamazepine, epilepsy, lacosamide, phase III, vimpat
A Phase III non-inferiority study comparing UCB’s Vimpat with carbamazepine suggests the two drugs can be used as monotherapy treatments. …
Genzyme’s Lemtrada shows five-year efficacy in extended trials
October 8, 2015Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis
Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …
Infectious diseases dominate Nobel Prize awards for medicine
October 8, 2015Manufacturing and Production, Research and Development Nobel Prize, artemisinin, ivermectin, malaria, mectizan, river blindness
Pharma researchers have been awarded the 2015 Nobel Prize for their work on a river blindness treatment, along with work …
Multiple Sclerosis treatment will be a $20bn market by 2024
October 7, 2015Research and Development multiple sclerosis
The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion …
Experts call for greater urgency in MS treatment
October 7, 2015Research and Development multiple sclerosis
A therapeutic strategy in multiple sclerosis (MS) that aims to maximise lifelong brain health (neurological reserve) needs to be widely …
PROFILE: Ambitious Ferring wants to be global fertility leader
October 7, 2015Manufacturing and Production, Research and Development Ferring, peptides
The stunning view of the Alps across Lake Geneva from Ferring’s corporate headquarters in Saint-Prex seems appropriate for a company …
AmerisourceBergen acquires sterile compounder PharMEDium for $2.5bn
October 7, 2015Research and Development, Sales and Marketing AmerisourceBergen, mergers and acquisitions
AmerisourceBergen will now source compounded drugs for its hospital clients by manufacturing them itself after spending more than $2.5 billion …
Akebia passes vadadustat for anaemia phase III study with FDA & EMA
October 7, 2015Research and Development Akabia, FDA, anaemia
Akebia Therapeutics has announced the successful completion of the End-of-Phase II Meeting process with the FDA and the Scientific Advice …
Rondo AG appoints Joachim Hoeltz as chief exec
October 7, 2015Manufacturing and Production, Research and Development, Sales and Marketing
Joachim Hoeltz has been appointed chief executive at pharmaceutical packaging company Rondo AG within the Business Area Medipak Systems. He …
NICE approves Merck’s Keytruda for advanced skin cancer following ipilimumab treatment
October 7, 2015Research and Development Merck, NHS, NICE, keytruda, skin cancer
The National Institute for Health and Care Excellence (NICE) has approved Merck’s Keytruda (pembrolizumab) for treating advanced skin cancer after …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
